Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIIPL DTwP-HepB-rPV-Hib Vaccine vs HEXASIIL in Healthy Toddlers and Infants
NCT07855172Phase 2Not yet recruiting
- Sponsor
- Serum Institute of India
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Serum Institute of India. Primary endpoint: Incidence, severity and relationship of solicited and unsolicited Adverse Events at 28 days. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT07855172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855172.